| pubmed-article:15570078 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15570078 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:15570078 | lifeskim:mentions | umls-concept:C0439849 | lld:lifeskim |
| pubmed-article:15570078 | lifeskim:mentions | umls-concept:C0034802 | lld:lifeskim |
| pubmed-article:15570078 | lifeskim:mentions | umls-concept:C0205145 | lld:lifeskim |
| pubmed-article:15570078 | lifeskim:mentions | umls-concept:C0009404 | lld:lifeskim |
| pubmed-article:15570078 | lifeskim:mentions | umls-concept:C0003250 | lld:lifeskim |
| pubmed-article:15570078 | lifeskim:mentions | umls-concept:C1522484 | lld:lifeskim |
| pubmed-article:15570078 | lifeskim:mentions | umls-concept:C0449438 | lld:lifeskim |
| pubmed-article:15570078 | lifeskim:mentions | umls-concept:C0036525 | lld:lifeskim |
| pubmed-article:15570078 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:15570078 | lifeskim:mentions | umls-concept:C0445223 | lld:lifeskim |
| pubmed-article:15570078 | lifeskim:mentions | umls-concept:C1552599 | lld:lifeskim |
| pubmed-article:15570078 | lifeskim:mentions | umls-concept:C1704787 | lld:lifeskim |
| pubmed-article:15570078 | lifeskim:mentions | umls-concept:C0205225 | lld:lifeskim |
| pubmed-article:15570078 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
| pubmed-article:15570078 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
| pubmed-article:15570078 | pubmed:issue | 23 | lld:pubmed |
| pubmed-article:15570078 | pubmed:dateCreated | 2004-11-30 | lld:pubmed |
| pubmed-article:15570078 | pubmed:abstractText | We hypothesized that the detection of epidermal growth factor receptor (EGFR) expression performed in primary tumors for treatment with EGFR-targeted monoclonal antibodies could not always correlate with EGFR status in metastatic sites, thus making cancer cells in these sites resistant to therapy. The aim of our study was to correlate EGFR expression on primary tumors and related metastases in order to find out whether assessing EGFR status on primary cancer is to be considered an effective tool for planning treatment with EGFR-targeted antibodies. | lld:pubmed |
| pubmed-article:15570078 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15570078 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15570078 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15570078 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15570078 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15570078 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15570078 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15570078 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15570078 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:15570078 | pubmed:issn | 0732-183X | lld:pubmed |
| pubmed-article:15570078 | pubmed:author | pubmed-author:CascinuStefan... | lld:pubmed |
| pubmed-article:15570078 | pubmed:author | pubmed-author:FabrisGuidalb... | lld:pubmed |
| pubmed-article:15570078 | pubmed:author | pubmed-author:ScartozziMari... | lld:pubmed |
| pubmed-article:15570078 | pubmed:author | pubmed-author:BearziItaloI | lld:pubmed |
| pubmed-article:15570078 | pubmed:author | pubmed-author:BerardiRossan... | lld:pubmed |
| pubmed-article:15570078 | pubmed:author | pubmed-author:MandolesiAles... | lld:pubmed |
| pubmed-article:15570078 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15570078 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:15570078 | pubmed:volume | 22 | lld:pubmed |
| pubmed-article:15570078 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15570078 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15570078 | pubmed:pagination | 4772-8 | lld:pubmed |
| pubmed-article:15570078 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:15570078 | pubmed:meshHeading | pubmed-meshheading:15570078... | lld:pubmed |
| pubmed-article:15570078 | pubmed:meshHeading | pubmed-meshheading:15570078... | lld:pubmed |
| pubmed-article:15570078 | pubmed:meshHeading | pubmed-meshheading:15570078... | lld:pubmed |
| pubmed-article:15570078 | pubmed:meshHeading | pubmed-meshheading:15570078... | lld:pubmed |
| pubmed-article:15570078 | pubmed:meshHeading | pubmed-meshheading:15570078... | lld:pubmed |
| pubmed-article:15570078 | pubmed:meshHeading | pubmed-meshheading:15570078... | lld:pubmed |
| pubmed-article:15570078 | pubmed:meshHeading | pubmed-meshheading:15570078... | lld:pubmed |
| pubmed-article:15570078 | pubmed:meshHeading | pubmed-meshheading:15570078... | lld:pubmed |
| pubmed-article:15570078 | pubmed:meshHeading | pubmed-meshheading:15570078... | lld:pubmed |
| pubmed-article:15570078 | pubmed:meshHeading | pubmed-meshheading:15570078... | lld:pubmed |
| pubmed-article:15570078 | pubmed:meshHeading | pubmed-meshheading:15570078... | lld:pubmed |
| pubmed-article:15570078 | pubmed:meshHeading | pubmed-meshheading:15570078... | lld:pubmed |
| pubmed-article:15570078 | pubmed:meshHeading | pubmed-meshheading:15570078... | lld:pubmed |
| pubmed-article:15570078 | pubmed:meshHeading | pubmed-meshheading:15570078... | lld:pubmed |
| pubmed-article:15570078 | pubmed:meshHeading | pubmed-meshheading:15570078... | lld:pubmed |
| pubmed-article:15570078 | pubmed:meshHeading | pubmed-meshheading:15570078... | lld:pubmed |
| pubmed-article:15570078 | pubmed:meshHeading | pubmed-meshheading:15570078... | lld:pubmed |
| pubmed-article:15570078 | pubmed:meshHeading | pubmed-meshheading:15570078... | lld:pubmed |
| pubmed-article:15570078 | pubmed:meshHeading | pubmed-meshheading:15570078... | lld:pubmed |
| pubmed-article:15570078 | pubmed:meshHeading | pubmed-meshheading:15570078... | lld:pubmed |
| pubmed-article:15570078 | pubmed:meshHeading | pubmed-meshheading:15570078... | lld:pubmed |
| pubmed-article:15570078 | pubmed:meshHeading | pubmed-meshheading:15570078... | lld:pubmed |
| pubmed-article:15570078 | pubmed:meshHeading | pubmed-meshheading:15570078... | lld:pubmed |
| pubmed-article:15570078 | pubmed:meshHeading | pubmed-meshheading:15570078... | lld:pubmed |
| pubmed-article:15570078 | pubmed:meshHeading | pubmed-meshheading:15570078... | lld:pubmed |
| pubmed-article:15570078 | pubmed:meshHeading | pubmed-meshheading:15570078... | lld:pubmed |
| pubmed-article:15570078 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15570078 | pubmed:articleTitle | Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. | lld:pubmed |
| pubmed-article:15570078 | pubmed:affiliation | Clinica di Oncologia Medica, Istituto di Anatomia Patologica, Azienda Ospedaliera Ospedali Riuniti, Ancona, Italy. | lld:pubmed |
| pubmed-article:15570078 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15570078 | pubmed:publicationType | Comparative Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15570078 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15570078 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15570078 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15570078 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15570078 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15570078 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15570078 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15570078 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15570078 | lld:pubmed |
